Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 plus docetaxel dose-finding and randomized phase II study in androgen-independent prostate cancer
ACTRN12607000307404Phase 2Recruiting
- Start
- Jul 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Muparfostat, docetaxel and prednisone in castration-resistant prostate cancer (CRPC) (6 arms). Primary endpoints: Safety and Efficacy. Started Jul 2005; status: recruiting.
02
Drugs
Muparfostatdocetaxelprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ACTRN12607000307404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000307404.